Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | MCLA-145 |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | Advanced Solid Tumor | predicted - sensitive | MCLA-145 | Phase I | Actionable | In a Phase I trial, MCLA-145 treatment demonstrated safety and activity in patients with CD274 (PD-L1)-positive advanced solid tumors (n=52), resulting in 5 partial responses (1 each in glioblastoma, sarcoma, cervical cancer, anal cancer, and gastric cancer) and a disease control rate of 37% (J Clin Oncol 42, 2024 (suppl 16; abstr 2520); NCT03922204). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab. | Full reference... |